Hallmarks of Cancer
Cancer biology centers on a key question: what makes a normal cell become cancerous? The answer involves a defined set of cellular capabilities, called the hallmarks of cancer, that cells must acquire during tumor development. Understanding these hallmarks gives you a framework for thinking about how cancers arise, progress, and can potentially be targeted by therapy.
Hallmarks of Cancer Cells
In 2000, Hanahan and Weinberg proposed a set of core capabilities that virtually all cancers share. The list has since expanded to ten hallmarks. Each one represents a distinct way cancer cells break normal rules.
- Sustaining proliferative signaling: Normal cells only divide when they receive external growth signals. Cancer cells generate their own, often through activation of oncogenes like RAS or MYC, or through inactivation of tumor suppressors like p53 or PTEN. The result is continuous, self-driven division.
- Evading growth suppressors: Cell cycle checkpoints exist to stop division when something is wrong. Cancer cells bypass these brakes, typically by inactivating tumor suppressor genes like RB (which gates the G1/S transition) or p53 (which responds to DNA damage).
- Resisting cell death: Apoptosis is the cell's built-in self-destruct program. Cancer cells disable it by upregulating anti-apoptotic proteins (e.g., Bcl-2) or downregulating pro-apoptotic proteins (e.g., Bax), allowing damaged cells to survive when they normally wouldn't.
- Enabling replicative immortality: Normal cells can only divide a limited number of times before their telomeres shorten to a critical length (the Hayflick limit). Cancer cells overcome this by reactivating telomerase (~85–90% of cancers) or using the alternative lengthening of telomeres (ALT) mechanism, giving them unlimited replicative potential.
- Inducing angiogenesis: Tumors can't grow beyond ~1–2 mm without a blood supply. Cancer cells secrete pro-angiogenic factors like VEGF and FGF to stimulate new blood vessel formation, ensuring oxygen and nutrient delivery.
- Activating invasion and metastasis: Cancer cells acquire the ability to leave the primary tumor, invade surrounding tissue, and colonize distant organs. This often involves epithelial-to-mesenchymal transition (EMT), where cells lose cell-cell adhesion and gain migratory properties, along with secretion of matrix metalloproteinases (MMPs) that degrade the extracellular matrix.
- Deregulating cellular energetics: Even when oxygen is available, many cancer cells preferentially use glycolysis for energy production rather than oxidative phosphorylation. This is called the Warburg effect. While less efficient per glucose molecule, it generates biosynthetic intermediates that support rapid growth.
- Avoiding immune destruction: The immune system can recognize and kill abnormal cells, but cancer cells develop evasion strategies. These include downregulating MHC class I molecules (so cytotoxic T cells can't recognize them) and expressing immunosuppressive ligands like PD-L1 (which shuts down T cell activity).
- Tumor-promoting inflammation: Chronic inflammation in the tumor microenvironment actually helps cancer progress. Recruited immune cells can paradoxically secrete growth factors, pro-angiogenic signals, and enzymes that remodel tissue to favor tumor expansion.
- Genome instability and mutation: Cancer cells often have defects in DNA repair pathways, leading to a high mutational burden. This genomic instability accelerates the accumulation of further mutations, fueling tumor evolution and heterogeneity.
Process of Oncogenic Transformation
Oncogenic transformation is the multi-step process by which a normal cell acquires enough alterations to become cancerous. It doesn't happen all at once. Instead, cells accumulate changes over time, with each change providing a selective growth advantage.
Two categories of alterations drive transformation:
- Genetic alterations directly change the DNA sequence. These include gain-of-function mutations in proto-oncogenes (converting them to active oncogenes, e.g., RAS, MYC) and loss-of-function mutations in tumor suppressor genes (e.g., p53, PTEN). Remember that oncogenes typically need only one mutant allele to drive cancer (dominant), while tumor suppressors usually require both alleles to be lost (Knudson's two-hit hypothesis).
- Epigenetic alterations change gene expression without altering the DNA sequence itself. These include abnormal DNA methylation (e.g., hypermethylation silencing tumor suppressors), altered histone modifications, and dysregulated non-coding RNAs. Epigenetic changes are reversible, which makes them attractive therapeutic targets.
As these alterations accumulate, normal cellular functions like cell cycle control and differentiation break down. The transformed cell progressively acquires the hallmarks described above, eventually becoming fully malignant.
Genetic Changes in Cancer Development
Several types of genetic changes contribute to cancer, and you should be able to distinguish them:
- Point mutations: Single nucleotide changes that can activate an oncogene (e.g., a single amino acid substitution in KRAS at codon 12) or inactivate a tumor suppressor.
- Chromosomal aberrations: Large-scale structural changes including translocations (e.g., the Philadelphia chromosome BCR-ABL fusion in chronic myeloid leukemia), deletions (loss of tumor suppressor regions), and gene amplifications (extra copies of oncogenes like HER2 in some breast cancers).
- Copy number variations (CNVs): Changes in the number of copies of specific genes or genomic regions, which can increase oncogene dosage or delete tumor suppressors.
These mutations can be germline (inherited and present in every cell, like BRCA1 mutations that predispose to breast cancer) or somatic (acquired during a person's lifetime in specific cells). Most cancers arise from somatic mutations that accumulate progressively over years or decades, which is why cancer incidence increases with age.
Role of the Tumor Microenvironment
A tumor is not just cancer cells. It's an ecosystem of diverse cell types, signaling molecules, and structural components that collectively influence whether a tumor grows, spreads, or gets eliminated. This tumor microenvironment (TME) plays a critical role in cancer progression.
Cellular components of the TME:
- Stromal cells: Cancer-associated fibroblasts (CAFs), endothelial cells (lining blood vessels), and pericytes (supporting vessel walls). CAFs are particularly important because they secrete growth factors and cytokines that promote tumor growth and angiogenesis.
- Immune cells: Tumor-associated macrophages (TAMs), T cells, regulatory T cells (Tregs), and natural killer (NK) cells. Their effects can cut both ways.
- Extracellular matrix (ECM): A structural scaffold of collagen, fibronectin, and proteoglycans. Remodeling of the ECM by MMPs and other enzymes creates physical space for tumor invasion and releases growth factors trapped in the matrix.
Immune cells in the TME can help or hinder the tumor:
- TAMs frequently adopt an M2-like phenotype, which promotes tumor growth, suppresses immune responses, and stimulates angiogenesis (contrast this with M1 macrophages, which are pro-inflammatory and anti-tumor).
- Tregs accumulate in tumors and suppress the activity of cytotoxic T cells that would otherwise attack cancer cells.
- Cytotoxic T cells and NK cells can kill cancer cells, but the immunosuppressive TME often renders them ineffective.
Hypoxia and metabolism in the TME:
The interior of a growing tumor is often oxygen-poor (hypoxic) because blood vessel formation can't keep pace with tumor growth. Hypoxia activates hypoxia-inducible factors (HIFs), which trigger angiogenesis, metabolic reprogramming, and increased invasiveness. The TME also engages in metabolic cross-talk with cancer cells. In the reverse Warburg effect, stromal cells (especially CAFs) undergo aerobic glycolysis and export lactate, which cancer cells then use as fuel for oxidative phosphorylation.